Wed, December 20, 2017
Tue, December 19, 2017
Mon, December 18, 2017
Fri, December 15, 2017
Thu, December 14, 2017
Wed, December 13, 2017
Tue, December 12, 2017
Mon, December 11, 2017
Fri, December 8, 2017
Thu, December 7, 2017
Wed, December 6, 2017
Tue, December 5, 2017
Mon, December 4, 2017
Fri, December 1, 2017
Thu, November 30, 2017
Wed, November 29, 2017
Tue, November 28, 2017
Mon, November 27, 2017
Wed, November 22, 2017
Tue, November 21, 2017
Mon, November 20, 2017
Fri, November 17, 2017
Thu, November 16, 2017

John Newman Initiated (BLUE) at Strong Buy and Held Target at $202 on, Dec 5th, 2017


//stocks-investing.news-articles.net/content/201 .. -buy-and-held-target-at-202-on-dec-5th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


John Newman of Canaccord Genuity, Initiated "bluebird bio, Inc." (BLUE) at Strong Buy and Held Target at $202 on, Dec 5th, 2017.

John has made no other calls on BLUE in the last 4 months.



There are 7 other peers that have a rating on BLUE. Out of the 7 peers that are also analyzing BLUE, 3 agree with John's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold on, Monday, November 6th, 2017
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold on, Friday, November 3rd, 2017
  • Biren Amin of "Jefferies" Downgraded from Strong Buy to Hold on, Wednesday, October 11th, 2017


These are the ratings of the 4 analyists that currently disagree with John


  • Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $200 on, Thursday, November 30th, 2017
  • Dane Leone of "BTIG" Upgraded from Hold to Strong Buy on, Thursday, November 2nd, 2017
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $162 on, Thursday, November 2nd, 2017
  • Matthew Luchini of "BMO Capital" Maintained at Buy with Increased Target to $162 on, Monday, October 30th, 2017

Publication Contributing Sources